Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2011) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Bendamustine in the treatment of chronic lymphocytic leukemia

(2009) Wolfgang Knauf   Expert Review of Anticancer Therapy

Bendamustine: Rebirth of an Old Drug

(2009) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2009) Wolfgang U. Knauf et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

(2008) L. M. Leoni et al.   CLINICAL CANCER RESEARCH

Bendamustine in Chronic Lymphocytic Leukemia and Refractory Lymphoma

(2008) Mathias J. Rummel   SEMINARS IN HEMATOLOGY